Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000032020 | SCV000630321 | uncertain significance | Biotinidase deficiency | 2023-12-05 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 413 of the BTD protein (p.Gly413Ser). This variant is present in population databases (rs374141881, gnomAD 0.003%). This missense change has been observed in individual(s) with partial biotinidase deficiency (PMID: 25144890). ClinVar contains an entry for this variant (Variation ID: 38577). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BTD protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Counsyl | RCV000032020 | SCV000800639 | uncertain significance | Biotinidase deficiency | 2017-12-14 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003480039 | SCV004226053 | uncertain significance | not provided | 2021-12-22 | criteria provided, single submitter | clinical testing | PP3, PM2 |
Natera, |
RCV000032020 | SCV001461223 | uncertain significance | Biotinidase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |